Gambogic Acid Is a Tissue-Specific Proteasome Inhibitor In Vitro and In Vivo

Cell Reports

Volumn 3, Issue 1, 2013, Pages 211-222

  Li, Xiaofen ^a   Liu, Shouting ^a   Huang, Hongbiao ^a   Liu, Ningning ^a   Zhao, Chong ^a   Liao, Siyan ^a   Yang, Changshan ^a   Liu, Yurong ^a   Zhao, Canguo ^a   Li, Shujue ^a   Lu, Xiaoyu ^a   Liu, Chunjiao ^a   Guan, Lixia ^a   Zhao, Kai ^a   Shi, Xiaoqing ^a   Song, Wenbin ^a   Zhou, Ping ^a   Dong, Xiaoxian ^a   Guo, Haiping ^a   Wen, Guanmei ^a   Zhang, Change ^a   Jiang, Lili ^a   Ma, Ningfang ^a   Li, Bing ^a   Wang, Shunqing ^a   Tan, Huo ^a   Wang, Xuejun ^b   Dou, Q Ping ^c   Liu, Jinbao ^a   more..

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; GAMBOGIC ACID; GREEN FLUORESCENT PROTEIN; MG 262; PRODRUG; PROTEASOME; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; TRYPSIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN K 562; CELL SURVIVAL; CONTROLLED STUDY; CYP2E1 GENE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; SOLID TUMOR; STRUCTURE ANALYSIS; TISSUE SPECIFICITY; TUMOR GENE;

ANIMALS; CASPASES; CELL DEATH; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEP G2 CELLS; HUMANS; K562 CELLS; LEUKEMIA; LYMPHOCYTES; MICE; MOLECULAR DOCKING SIMULATION; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRYPSIN; UBIQUITINATION; XANTHONES;

EID: 84873194524     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.11.023     Document Type: Article

References (25)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
2. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59:2615-2622.
3. Choudhary D., Jansson I., Stoilov I., Sarfarazi M., Schenkman J.B. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. 2005, 436:50-61.
4. Feng F., Liu W., Wang Y., Guo Q., You Q. Structure elucidation of metabolites of gambogic acid in vivo in rat bile by high-performance liquid chromatography-mass spectrometry and high-performance liquid chromatography-nuclear magnetic resonance. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 860:218-226.
5. Groll M., Bochtler M., Brandstetter H., Clausen T., Huber R. Molecular machines for protein degradation. ChemBioChem 2005, 6:222-256.
6. Gruenwald T.B.J., Jaenicke C. PDR for Herbal Medicines 2000, Medical Economics, Montvale, NJ, pp. 325-326. Second Edition.
7. Guo Q.L., Zhao L., Wu Z.Q., You Q.D., Yu G., Zhang Q. Effect of gambogic acid on the hemopoietic and immune function in experimental animals. Chin. J. Nat. Med. 2003, 1:229-231.
8. Guo Q., Qi Q., You Q., Gu H., Zhao L., Wu Z. Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin. Pharmacol. Toxicol. 2006, 99:178-184.
9. Hao K., Liu X.Q., Wang G.J., Zhao X.P. Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur. J. Drug Metab. Pharmacokinet. 2007, 32:63-68.
10. Huang H., Chen D., Li S., Li X., Liu N., Lu X., Liu S., Zhao K., Zhao C., Guo H., et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011, 301:221-228.
11. Huang H., Liu N., Zhao K., Zhu C., Lu X., Li S., Lian W., Zhou P., Dong X., Zhao C., et al. Sanggenon C decreases tumor cell viability associated with proteasome inhibition. Front. Biosci. 2011, 3:1315-1325.
12. Kot M., Daniel W.A. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol. Rep. 2009, 61:1216-1220.
13. Liu Y.T., Hao K., Liu X.Q., Wang G.J. Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol. Sin. 2006, 27:1253-1258.
14. Nagai F., Hiyoshi Y., Sugimachi K., Tamura H.O. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol. Pharm. Bull. 2002, 25:383-385.
15. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525.
16. Qi Q., You Q., Gu H., Zhao L., Liu W., Lu N., Guo Q. Studies on the toxicity of gambogic acid in rats. J. Ethnopharmacol. 2008, 117:433-438.
17. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352:2487-2498. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.
18. Tang Z.Y., Wu Y.L., Gao S.L., Shen H.W. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J. Surg. Res. 2008, 145:111-123.
19. Yang H., Zhou P., Huang H., Chen D., Ma N., Cui Q.C., Shen S., Dong W., Zhang X., Lian W., et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer 2009, 124:2450-2459.
20. Yang J., Ding L., Jin S., Liu X., Liu W., Wang Z. Identification and quantitative determination of a major circulating metabolite of gambogic acid in human. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:659-666.
21. Yang J., Ding L., Hu L., Qian W., Jin S., Sun X., Wang Z., Xiao W. Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition. Drug Metab. Dispos. 2011, 39:617-626.
22. Yi T., Yi Z., Cho S.G., Luo J., Pandey M.K., Aggarwal B.B., Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008, 68:1843-1850.
23. Yu L.J., Matias J., Scudiero D.A., Hite K.M., Monks A., Sausville E.A., Waxman D.J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 2001, 29:304-312.
24. Zhang H.Z., Kasibhatla S., Wang Y., Herich J., Guastella J., Tseng B., Drewe J., Cai S.X. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg. Med. Chem. 2004, 12:309-317.
25. Zhou Z.T., Wan J.W. Phase I human tolerability trial of gambogic acid. Chin. J. New Drugs 2007, 1:679-682.